Summary Milo Biotechnology LLC (Milo) is a biotechnology company that develops novel therapies based on follistatin, a protein that increases muscle mass and strength.The company’s pipeline product includes AAV1 (based on adeno-associated virus), which is a gene therapy for the one time treatment option for muscle wasting diseases targeting becker muscular dystrophy, inclusive body myositis and duchenne muscular dystrophy.
Milo utilizes AAV technology, which is a gene therapy-based up-regulation of the muscle-strengthening follistatin protein and is exclusively licensed from Nationwide Children’s Hospital, Ohio.The company is also developing a drug named AAV9 for the treatment of Atrophy.
Milo is headquartered in Cleveland Heights, Ohio, the US.
Milo Biotechnology LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Obesity - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape. Obesity is defined as having an excessive amount of body fat. Obesity increases...
Therapeutic Drug Monitoring Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Therapeutic Drug Monitoring Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Therapeutic Drug Monitoring Tests pipeline products with...
Hepatitis B - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2020, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape. Hepatitis B is a potentially life-threatening liver infection...
The Global Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies. Comprehensive directory of diagnostic deals since 2014 Diagnostic contract documents Diagnostic...
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes - Pipeline Review, H2 2020, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape. Type 1 diabetes (T1D) is an autoimmune...
The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors...
Diabetes Assays - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Diabetes Assays - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Diabetes Assays pipeline products with comparative analysis of the products at various stages...